DILIA STEVENS: Open Payments
NPI 1700523867 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$338 in 15 payments from 9 companies in 2025. Trend: 2023 $226 · 2024 $142 · 2025 $338
Food & beverage: $338
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $85 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| UCB, Inc. | 2 | $59 |
| Corcept Therapeutics | 2 | $30 |
| Verona Pharma, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Gilead Sciences, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
Products named: Wegovy, Fintepla, OPSYNVI, Korlym, Ohtuvayre, OPSUMIT, ENTYVIO, Kerendia.
Industry payments across AZ — which companies pay providers there.
